Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018203127) COMPOSITIONS FOR TREATMENT OF MALIGNANT TUMORS AND PRECANCEROUS CONDITIONS, METHODS OF USE THEREOF AND METHODS FOR MANUFACTURING MEDICAMENTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/203127 International Application No.: PCT/IB2018/000456
Publication Date: 08.11.2018 International Filing Date: 04.05.2018
IPC:
A61K 31/675 (2006.01) ,A61K 31/4415 (2006.01) ,A61K 31/4425 (2006.01) ,A61P 35/00 (2006.01) ,C07D 213/67 (2006.01) ,C07D 213/89 (2006.01) ,C07F 9/58 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
66
Phosphorus compounds
675
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4415
Pyridoxine, i.e.vitamin B6
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4425
Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
213
Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02
having three double bonds between ring members or between ring members and non-ring members
04
having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
62
Oxygen or sulfur atoms
63
One oxygen atom
65
attached in position 3 or 5
66
having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulfur, or nitrogen atom, e.g. pyridoxal
67
2-Methyl-3-hydroxy-4,5-bis (hydroxy-methyl) pyridine, i.e. pyridoxine
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
213
Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02
having three double bonds between ring members or between ring members and non-ring members
89
with hetero atoms directly attached to the ring nitrogen atom
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
F
ACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9
Compounds containing elements of the 5th Group of the Periodic System
02
Phosphorus compounds
547
Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
553
having one nitrogen atom as the only ring hetero atom
576
Six-membered rings
58
Pyridine rings
Applicants:
FIRMIANA HEALTH SCIENCES INC. [CA/CA]; 2135-12191 Hammersmith Way Richmond, British Columbia V7A 5H2, CA
Inventors:
NUMATA, Masayuki; CA
FAN, Hung-Yi; CA
LI, Aidi; CA
Priority Data:
62/501,02503.05.2017US
Title (EN) COMPOSITIONS FOR TREATMENT OF MALIGNANT TUMORS AND PRECANCEROUS CONDITIONS, METHODS OF USE THEREOF AND METHODS FOR MANUFACTURING MEDICAMENTS
(FR) COMPOSITIONS POUR LE TRAITEMENT DE TUMEURS MALIGNES ET D'ÉTATS PRÉCANCÉREUX, PROCÉDÉS D'UTILISATION DE CELLES-CI ET PROCÉDÉS DE FABRICATION DE MÉDICAMENTS
Abstract:
(EN) The invention describes compositions and methods of use for pyrithione compounds and pharmacologically acceptable salts thereof. The invention provides topical administration methods for treating skin cancers, treating cervical cancer, treating other cancers, preventing skin cancer development from precancerous skin conditions, preventing cervical cancer development from chronic human papillomavirus (HPV) infection, preventing development of other cancers from chronic HPV infection. Also disclosed are compositions comprising at least one pyrithione compound, ethylenediaminetetraacetic acid (EDTA), ascorbic acid, any salt and chemical derivatives thereof, pyridoxine and any derivative thereof and pharmacologically acceptable buffers. In these compositions, pH of the compositions is adjusted to between 4.5 and 6.4.
(FR) La présente invention concerne des compositions et des procédés d'utilisation de composés de pyrithione et des sels pharmacologiquement acceptables de ceux-ci. La présente invention concerne des procédés d'administration topique pour le traitement de cancers de la peau, le traitement du cancer du col de l'utérus, le traitement d'autres cancers, la prévention du développement du cancer de la peau à partir de conditions de peau précancéreuses, la prévention du développement du cancer du col de l'utérus à partir d'une infection par le papillomavirus humain (PVH) chronique, la prévention du développement d'autres cancers à partir d'une infection par le PVH chronique. La présente invention concerne également des compositions comprenant au moins un composé de pyrithione, de l'acide éthylènediaminetétracétique (EDTA), de l'acide ascorbique, tout sel et dérivé chimique de ceux-ci, de la pyridoxine et tout dérivé de celle-ci et des tampons pharmacologiquement acceptables. Dans ces compositions, le pH des compositions est ajusté entre 4,5 et 6,4.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)